(Q34782774)

4 August 2017

1 reference

title

Drug development of MET inhibitors: targeting oncogene addiction and expedience (English)

1 reference

4 August 2017

Silvia Giordano

2

0 references

Paolo M. Comoglio

object named as

Paolo M Comoglio

series ordinal

1

0 references

author name string

Livio Trusolino

series ordinal

3

1 reference

4 August 2017

1 June 2008

1 reference

Nature Reviews Drug Discovery

4 August 2017

1 reference

4 August 2017

7

1 reference

4 August 2017

504-516

1 reference

4 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2530

4 August 2017

0 references

cites work

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

1 reference

Met, metastasis, motility and more

31 March 2020

1 reference

Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B

31 March 2020

1 reference

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

31 March 2020

1 reference

Co-expression of theHGF/SF andc-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis

31 March 2020

1 reference

Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development

31 March 2020

1 reference

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

31 March 2020

1 reference

Scatter factor/hepatocyte growth factor is essential for liver development

31 March 2020

1 reference

31 March 2020

1 reference

Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

31 March 2020

1 reference

Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis.

31 March 2020

1 reference

Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?

31 March 2020

1 reference

Hepatocyte growth factor gene therapy of liver cirrhosis in rats

31 March 2020

1 reference

Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis.

31 March 2020

1 reference

Invasive growth: a MET-driven genetic programme for cancer and stem cells

31 March 2020

1 reference

Invasive growth: from development to metastasis

31 March 2020

1 reference

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

31 March 2020

1 reference

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

31 March 2020

1 reference

Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors

31 March 2020

1 reference

The MET oncogene drives a genetic programme linking cancer to haemostasis

31 March 2020

1 reference

The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions

31 March 2020

1 reference

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

31 March 2020

1 reference

Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma.

31 March 2020

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice

31 March 2020

1 reference

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

31 March 2020

1 reference

A novel germ line juxtamembrane Met mutation in human gastric cancer

31 March 2020

1 reference

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

31 March 2020

1 reference

Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele

31 March 2020

1 reference

Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.

31 March 2020

1 reference

The hepatocyte growth factor regulatory factors in human breast cancer

31 March 2020

1 reference

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

31 March 2020

1 reference

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation

31 March 2020

1 reference

Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor

31 March 2020

1 reference

Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.

31 March 2020

1 reference

Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.

31 March 2020

1 reference

Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses.

31 March 2020

1 reference

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

31 March 2020

1 reference

Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling

31 March 2020

1 reference

Interactions between scatter factors and their receptors: hints for therapeutic applications

31 March 2020

1 reference

Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript

31 March 2020

1 reference

NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics

31 March 2020

1 reference

NK4 gene therapy targeting HGF-Met and angiogenesis.

31 March 2020

1 reference

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

31 March 2020

1 reference

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

31 March 2020

1 reference

The Sema domain of Met is necessary for receptor dimerization and activation

31 March 2020

1 reference

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

31 March 2020

1 reference

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

31 March 2020

1 reference

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

31 March 2020

1 reference

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

31 March 2020

1 reference

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

31 March 2020

1 reference

K252a inhibits the oncogenic properties of Met, the HGF receptor

31 March 2020

1 reference

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

31 March 2020

1 reference

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

31 March 2020

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

31 March 2020

1 reference

Tyrosine kinase signal specificity: lessons from the HGF receptor

31 March 2020

1 reference

A five-amino-acid peptide blocks Met- and Ron-dependent cell migration

31 March 2020

1 reference

Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions

31 March 2020

1 reference

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

31 March 2020

1 reference

Epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

31 March 2020

1 reference

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

31 March 2020

1 reference

Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells

31 March 2020

1 reference

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

31 March 2020

1 reference

Stromal fibroblasts in cancer initiation and progression

31 March 2020

1 reference

Angiogenesis inhibitors: motivators of metastasis?

31 March 2020

1 reference

Out of air is not out of action

31 March 2020

1 reference

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

31 March 2020

1 reference

Regulation of c-Met-dependent gene expression by PTEN

31 March 2020

1 reference

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

31 March 2020

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

31 March 2020

1 reference

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

31 March 2020

1 reference

Signaling networks assembled by oncogenic EGFR and c-Met

31 March 2020

1 reference

A matter of life and death

31 March 2020

1 reference

31 March 2020

Oncogenes and cell death

1 reference

Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2.

31 March 2020

1 reference

Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein

31 March 2020

1 reference

Hepatocyte growth factor induces pro-apoptotic genes in HepG2 hepatoma but not in B16-F1 melanoma cells

31 March 2020

1 reference

Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin

31 March 2020

1 reference

p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis

31 March 2020

1 reference

An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity.

31 March 2020

1 reference

CD44 is required for two consecutive steps in HGF/c-Met signaling.

31 March 2020

1 reference

Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin

31 March 2020

1 reference

A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth

31 March 2020

1 reference

Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis

31 March 2020

1 reference

Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth

31 March 2020

1 reference

The semaphorin 4D receptor controls invasive growth by coupling with Met

31 March 2020

1 reference

Interplay between scatter factor receptors and B plexins controls invasive growth

31 March 2020

1 reference

Sema4D induces angiogenesis through Met recruitment by Plexin B1

31 March 2020

1 reference

Expression of Met protein in thyroid tumours

31 March 2020

1 reference

Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage

31 March 2020

1 reference

Overexpression of the Met/HGF receptor in ovarian cancer.

31 March 2020

1 reference

Overexpression of the met/HGF receptor in renal cell carcinomas

31 March 2020

1 reference

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma

31 March 2020

1 reference

u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma

31 March 2020

1 reference

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

31 March 2020

1 reference

Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer

31 March 2020

1 reference

MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2530

1 reference

4 August 2017

1 reference

PubMed ID

18511928